BGLC · XBRL financial data

BioNexus Gene Lab financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BGLC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	2,554	2,273*	2,382	1,975	2,630	2,524*	2,137	2,260	2,544	484*	23	76
Cost of revenue	2,199	2,007*	2,017	1,686	2,304	2,215*	1,794	1,892	2,166	488*	24	63
Gross profit	354	267*	365	289	327	309*	343	368	378	(4)*	(1)	13
Research and development	—	year only	11	8	10	17*	12	13	15	11*	14	14
General and administrative	3,082	(17)*	646	760	2,130	(1,561)*	392	517	446	181*	328	299
Total operating expenses	—	year only	(646)	760	2,130	(8,471)*	(1,053)	1,189	1,188	1,052*	597	416
Operating income (loss)	(2,529)	258*	(79)	259	(1,338)	(416)*	(618)	(611)	(703)	(1,033)*	(540)	(282)
Interest expense	4	4*	5	4*	6	—	—	—	—	—	—	—
Other income (expense)	—	year only	202	730	466	675*	91	209	108	23*	58	—
Income tax expense (benefit)	76	(98)*	(20)	(56)	2	(81)*	0	0	0	0*	0	0
Net income (loss)	(2,609)	308*	(104)	199	(1,345)	(348)*	(623)	(616)	(709)	(1,036)*	(544)	(286)
Earnings per share, diluted USD per share	—	—	(0.01)	0.11	(0.75)	—	(0.04)	(0.34)	(0.40)	—	(0.23)	(0.12)
Weighted average shares, diluted thousands of shares	—	—	17,668	1,767	1,797	—	17,968	1,797	1,797	—	2,417	2,417

† Share count changed about 1/10 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (BGLC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	6,147	5,929	5,832	5,414	4,137	2,887	2,089	814	1,153	2,486	1,338	1,233
Accounts receivable	—	—	—	—	—	1,377	—	1,852	1,522	506	80	16
Inventory	1,108	1,138	1,077	1,033	1,389	1,389	1,179	1,216	1,007	677	667	653
Total current assets	8,270	8,047	7,905	7,843	7,039	7,430	6,542	6,379	5,627	5,449	5,196	4,943
Property and equipment, net	1,497	1,512	1,472	1,348	1,729	1,523	1,520	1,593	1,571	1,599	1,577	1,538
Right-of-use asset	148	142	128	242	233	215	204	200	186	178	163	147
Total assets	11,466	11,400	11,161	11,140	10,995	10,434	9,480	9,421	7,621	9,253	9,040	8,726
Accounts payable	1,570	1,402	1,429	955	1,033	1,503	1,183	—	—	—	—	—
Accrued liabilities	—	—	—	—	—	169	—	—	—	126	109	70
Total current liabilities	1,644	1,631	1,717	1,399	1,415	1,951	1,560	1,758	678	521	796	813
Lease liability, non-current	105	99	89	183	178	160	148	141	127	117	104	89
Total liabilities	1,778	1,742	1,817	1,594	1,607	2,111	1,708	1,899	805	638	947	948
Accumulated deficit	(1,781)	(1,844)	(1,948)	(1,749)	(3,094)	(3,443)	(4,066)	(4,682)	(5,391)	(6,427)	(6,971)	(7,257)
Total stockholders' equity	9,688	9,658	9,344	9,546	9,388	8,323	7,772	7,522	6,816	8,615	8,093	7,778
Total liabilities and equity	11,466	11,400	11,161	11,140	10,995	10,434	9,480	9,421	7,621	9,253	9,040	8,726
Common shares outstanding (cover page) thousands of shares	17,668	17,668	17,668	17,968	17,968	17,968	1,797	1,797	1,797	2,417	2,417	2,933

† Share count changed about 1/10 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (BGLC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,609)	308*	(104)	199	(1,345)	(348)*	(623)	(616)	(709)	(1,036)*	(544)	(286)
Stock-based compensation	—	—	—	—	—	0*	—	—	—	795*	—	—
Net cash from operating activities	(899)*	(262)*	(34)	(671)*	(1,460)*	(70)*	(824)	(738)*	(1,237)*	961*	(148)	(422)*
Purchases of property and equipment	134*	(148)*	22	2*	199*	4*	9	21*	5*	1*	0	0*
Net cash from investing activities	(361)*	(14)*	24	83*	(183)*	494*	(16)	(29)*	995*	(6)*	(14)	416*
Proceeds from issuing equity	—	—	—	—	—	—	—	—	—	year only	—	—
Net cash from financing activities	5,747*	11*	24	174*	(199)*	147*	(1)	(1)*	34*	267*	60	14*
Net change in cash	4,388*	(218)*	(97)	(418)*	(1,277)*	161*	(798)	(552)*	(180)*	1,129*	(88)	(6)*

† Share count changed about 1/10 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BioNexus Gene Lab	1,233	76	(422)*	2.9M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Aclarion	16,285	25	(2,657)*	2.9M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Advanced Biomed	386	year only	(583)*	1.7M	0.7 quarters	Q4 FY26 10-KJun 30, 2026
Ludwig Enterprises	18	not reported	(153)	167.2M	1.3 quarters	Q1 FY26 10-QMar 31, 2026
CapForce	144	50,000	(618)*	12.4M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
American Shared Hospital Services	6,511	8,430	2,236*	6.7M	—	Q2 FY26 10-QJun 30, 2026
Biodesix	29,996	26,861	(1,562)*	10.6M	19.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.